OncoMatch/Clinical Trials/NCT06385847
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
Is NCT06385847 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Zoladex and LY01005 for prostate cancer.
Treatment: Zoladex · LY01005 — The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: gnrh agonist (zoladex, ly01005)
Exception: gnrh agonists for < 6 months and discontinued for more than 6 months were allowed
Lab requirements
Blood counts
Hemoglobin ≥10 g/dL; Absolute neutrophil count ≥1.5 x 10^9/L; Platelet count ≥100 x 10^9/L
Kidney function
Serum creatinine ≤1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded
Liver function
AST/SGOT and/or ALT/SGPT ≤1.5 x ULN; Total bilirubin ≤1.5 x ULN
Adequate organ or bone marrow function as evidenced by: Hemoglobin ≥10 g/dL; Absolute neutrophil count ≥1.5 x 10^9/L; Platelet count ≥100 x 10^9/L; AST/SGOT and/or ALT/SGPT ≤1.5 x ULN; Total bilirubin ≤1.5 x ULN; Serum creatinine ≤1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify